Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 1;96(10):1264-1274.
doi: 10.1002/ajh.26295. Epub 2021 Aug 2.

An artificial intelligence-assisted diagnostic platform for rapid near-patient hematology

Affiliations

An artificial intelligence-assisted diagnostic platform for rapid near-patient hematology

Neta Bachar et al. Am J Hematol. .

Abstract

Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at the point-of-care. Sight OLO (Sight Diagnostics, Israel) is a novel hematological platform which provides a 19-parameter, five-part differential CBC, and is designed to address the limitations in current point-of-care hematology analyzers using recent advances in artificial intelligence (AI) and computer vision. Accuracy, repeatability, and flagging capabilities of OLO were compared with the Sysmex XN-Series System (Sysmex, Japan). Matrix studies compared performance using venous, capillary and direct-from-fingerprick blood samples. Regression analysis shows strong concordance between OLO and the Sysmex XN, demonstrating that OLO performs with high accuracy for all CBC parameters. High repeatability and reproducibility were demonstrated for most of the testing parameters. The analytical performance of the OLO hematology analyzer was validated in a multicenter clinical laboratory setting, demonstrating its accuracy and comparability to clinical laboratory-based hematology analyzers. Furthermore, the study demonstrated the validity of CBC analysis of samples collected directly from fingerpricks.

PubMed Disclaimer

Conflict of interest statement

Employment or Leadership: Yochay Eshel, S.D. Sight Diagnostics LTD; Daniel Levner, S.D. Sight Diagnostics LTD; Amir Zait, S.D. Sight Diagnostics LTD; Dan Glück, S.D. Sight Diagnostics LTD; Dana Benbassat, S.D. Sight Diagnostics LTD; Sharon Pecker, S.D. Sight Diagnostics LTD; David Brailovsky, S.D. Sight Diagnostics LTD; Evgeny Yurkovsky, S.D. Sight Diagnostics LTD; Neta Bachar, S.D. Sight Diagnostics LTD; Sarah Levy, S.D. Sight Diagnostics LTD. Cordelia Sever, Alexander Kratz, and Carlo Brugnara received research funding from S.D. Sight Diagnostics LTD in the form of a sponsored research agreement/contract. Yochay Eshel, Daniel Levner, Amir Zait, Dan Glück, Dana Benbassat, Sharon Pecker, David Brailovsky, Evgeny Yurkovsky, Neta Bachar, and Sarah Levyare S.D. Sight Diagnostics LTD employees and stockholders.

Figures

FIGURE 1
FIGURE 1
The Sight OLO hematology analyzer. (A) A rendering of the Sight OLO hematology analyzer (Sight Diagnostics, Israel), a desktop system measuring 284 mm × 255 mm × 324 mm. (B) Components of OLO's single‐use test kit: (1) cartridge, (2) mixing‐bottle, (3) dropper‐cap, (4) microcapillary. (C) Sample preparation workflow for fingerprick samples. (D,E) False‐colored micrographs collected using OLO's multispectral microscopy. Red channel: hemoglobin absorption; green channel: nuclear DNA fluorescence; blue channel: cytoplasmic staining. (D) Characteristic examples of different white blood cell types. (E) Characteristic examples of different anomalous cell types and formations [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2
FIGURE 2
Results of the method comparison study between the Sight OLO and the Sysmex XN hematology analyzers. Graphs indicate Pearson correlation, slope and bias for each parameter. These results are tabulated in Table S1 [Color figure can be viewed at wileyonlinelibrary.com]

References

    1. Luppa PB, Müller C, Schlichtiger A, Schlebusch H. Point‐of‐care testing (POCT): current techniques and future perspectives. TrAC Trends Anal Chem. 2011;30(6):887‐898. 10.1016/j.trac.2011.01.019 - DOI - PMC - PubMed
    1. Nichols JH. Quality in point‐of‐care testing. Expert Rev Mol Diagn. 2003;3(5):563‐572. - PubMed
    1. Larsson A, Greig‐Pylypczuk R, Huisman A. The state of point‐of‐care testing: a European perspective. Ups J Med Sci. 2015;120(1):1‐10. 10.3109/03009734.2015.1006347 - DOI - PMC - PubMed
    1. Abel G. Current status and future prospects of point‐of‐care testing around the globe. Expert Rev Mol Diagn. 2015;15(7):853‐855. 10.1586/14737159.2015.1060126 - DOI - PubMed
    1. Cals JWL, Schols AMR, van Weert HCPM, et al. Point‐of‐care testing in family practices: present use and need for tests in the future. Ned Tijdschr Geneeskd. 2014;158:A8210. - PubMed

Publication types